<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635020</url>
  </required_header>
  <id_info>
    <org_study_id>123123</org_study_id>
    <nct_id>NCT04635020</nct_id>
  </id_info>
  <brief_title>Comparison Of iStent to Laser in Exfoliation Glaucoma Helsinki Study Group</brief_title>
  <acronym>COILEH</acronym>
  <official_title>A Prospective Randomised Trial Comparing Selective Laser Trabeculoplasty (SLT) and iStent Trabecular Micro-bypass Stent Implantation Combined With Cataract Surgery in Exfoliation Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the efficacy of an iStent trabecular microbypass&#xD;
      stent compared to selective laser trabeculoplasty in combination with cataract surgery in&#xD;
      eyes with exfoliation glaucoma (EXF)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exfoliation glaucoma patients with significant cataracts are being informed about the study&#xD;
      and potential risks, all patients giving written informed consent will undergo screening to&#xD;
      determine eligibility for study entry. Patient´s glaucoma is classified into stable or&#xD;
      unstable glaucoma groups with their current glaucoma medication. Patients meeting the&#xD;
      eligibility requirements of stable glaucoma will be randomised to cataract surgery combined&#xD;
      with iStent (65 patients), II SLT (65 patients) or III cataract surgery alone (25 patients)&#xD;
      and patient with unstable glaucoma will be randomised to cataract surgery combined with I&#xD;
      iStent (65 patients), II SLT (65 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 2033</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Group I: Change in the number of IOP lowering medications compared to baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Accountability of IOP lowering medications used by the patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Group II: Change in the IOP compared to baseline</measure>
    <time_frame>12 months</time_frame>
    <description>IOP measured by Goldmann aplanation tonometry (GAT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group I: Change in the IOP compared to baseline</measure>
    <time_frame>12 months</time_frame>
    <description>IOP measured by GAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Group II: Change in the number of IOP lowering medications compared to baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Accountability of IOP lowering medications used by the patient</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Group I and II: Number of patients with secondary glaucoma surgery</measure>
    <time_frame>10 years</time_frame>
    <description>Number of patients with secondary glaucoma surgery at 10 years from baseline is counted</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Exfoliation Glaucoma</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Stable glaucoma iStent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract surgery combined with iStent inject</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable glaucoma SLT-laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract surgery combined with SLT-laser 1 month after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable glaucoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unstable glaucoma iStent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract surgery combined with iStent inject</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unstable glaucoma SLT-laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract surgery combined with SLT-laser 1 month after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>iStent</intervention_name>
    <description>2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork</description>
    <arm_group_label>Stable glaucoma iStent</arm_group_label>
    <arm_group_label>Unstable glaucoma iStent</arm_group_label>
    <other_name>Trabecular Micro-Bypass Stent System Model G2-M-IS, Glaukos Corporation, San Clemente, California</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SLT-laser</intervention_name>
    <description>1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)</description>
    <arm_group_label>Stable glaucoma SLT-laser</arm_group_label>
    <arm_group_label>Unstable glaucoma SLT-laser</arm_group_label>
    <other_name>Selective laser trabeculoplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Conventional cataract surgery</description>
    <arm_group_label>Stable glaucoma</arm_group_label>
    <arm_group_label>Stable glaucoma SLT-laser</arm_group_label>
    <arm_group_label>Stable glaucoma iStent</arm_group_label>
    <arm_group_label>Unstable glaucoma SLT-laser</arm_group_label>
    <arm_group_label>Unstable glaucoma iStent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent of information&#xD;
&#xD;
          -  Clinical significant cataract&#xD;
&#xD;
          -  Able to attend 12 month period&#xD;
&#xD;
          -  Mild to moderate exfoliation glaucoma according to European glaucoma society&#xD;
             guidelines (EGS)&#xD;
&#xD;
          -  Group I stable glaucoma (IOP within individual target IOP), and group II unstable&#xD;
             glaucoma (IOP above individual target IOP) with baseline glaucoma medication&#xD;
&#xD;
          -  Target IOP ≥16&#xD;
&#xD;
          -  Able to understand Finnish, Swedish or English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical set target IOP &lt; 16 mmHg in advanced glaucoma&#xD;
&#xD;
          -  Baseline IOP prior to enrolment ≥30 mmHg, and ≥3 glaucoma medications&#xD;
&#xD;
          -  Closed angle&#xD;
&#xD;
          -  Congenital angle anomaly&#xD;
&#xD;
          -  Clinically significant corneal dystrophy or other hindering corneal condition&#xD;
&#xD;
          -  Unable to use topical medical therapy&#xD;
&#xD;
          -  Central corneal thickness of less than 480um or more than 620um&#xD;
&#xD;
          -  Active uveitis, cystic macular edema (CME), exudative age-related macular&#xD;
             degeneration, proliferative diabetic retinopathy or clinical significant macular&#xD;
             edema, intraocular neoplasm, intraocular injections, intraocular lens luxation,&#xD;
             phacodonesis.&#xD;
&#xD;
          -  Previous intraocular surgery, refractive surgery or cycloablation&#xD;
&#xD;
          -  Two or more prior SLT or laser trabeculoplasty&#xD;
&#xD;
          -  Unable to participate due to another medical disease or condition&#xD;
&#xD;
          -  Participating in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Harju, MD, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eeva Ojanen, MD</last_name>
    <phone>+358503608589</phone>
    <email>eeva.ojanen@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eeva Ojanen, MD</last_name>
      <phone>+358 503608589</phone>
      <email>eeva.ojanen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Mika Harju, MD prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Prof. Mika Harju</investigator_full_name>
    <investigator_title>MD, professor</investigator_title>
  </responsible_party>
  <keyword>SLT</keyword>
  <keyword>iStent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

